Biomaxima S.A.

Manufacture of other chemical products n.e.c.

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2008-09-10
Share capital
4,193,118.00 PLN
Activity description

BioMaxima S.A. is a Polish, Warsaw Stock Exchange-listed manufacturer of microbiological media, reagents and in vitro diagnostics equipment. The company provides microbiology, molecular diagnostics and cell culture products, laboratory diagnostics and disposable materials. It also runs training courses for laboratories, including validation and verification of microbiological test methods and Legionella diagnostics.

Registered address
Vetterów 5, 20-277 Lublin, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-84069-43993-FVAGW-27

Financials

Total Operating Costs
14.69m
+19.1% vs 2024

Revenue history (in m)

Filing timeliness

1 of 6 financial statements was filed late (for 2023, 28 days late). All were audited by a statutory auditor.

  • 202517/06/2026
  • 202401/07/2025
  • 202312/08/2024
  • 202229/06/2023
  • 202115/06/2022
  • 202023/09/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 8.40
-0.10 (-1.18%)
8.408.458.508.4010:0012:0014:0016:00
Open
PLN 8.52
High
PLN 8.52
Low
PLN 8.40
Volume
2K
Avg. vol.
4.02K
Market cap
PLN 35.22M
P/E ratio
44.21
EPS
PLN 0.19
Shares outstanding
4.19M
52-week
PLN 8.40 – 9.41
Dividend yield
5.95%
Dividend
PLN 0.50
Ex dividend date
Jun 16, 2023
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 3.75mUSD 207.73kUSD 97.78k
Q1 2026USD 4.27mUSD 146.14kUSD 88.60k
Q4 2025USD 4.33mUSD 197.64kUSD 106.23k
Q3 2025USD 3.51mUSD -5.78kUSD -76.34k

Results for Q3 2026:Nov 30, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Sector · Manufacturing3,294 / 24,570
Top 13%
City · Lublin141 / 4,828
Top 2.9%
Voivodeship · Lubelskie370 / 10,176
Top 3.6%
Country · Poland13,767 / 297,266
Top 4.6%

Results vs industry

Revenue
This companyUSD 14.94mMedianUSD 638.23kAverageUSD 9.43m
Net profit
This companyUSD -43.95kMedianUSD 6.31kAverageUSD 97.67k
Operating costs
This companyUSD 14.69mMedianUSD 636.51kAverageUSD 9.00m
Assets
This companyUSD 19.73mMedianUSD 556.61kAverageUSD 6.76m

Offer

Websites

Public procurement

1008 tenders recorded as contractor: 728 national ($8,976,950) and 280 EU ($4,417,330).

SubjectAmount
Successive supply of microbiological culture media, cassette tests and tests for determining MIC for the microbiological diagnostics laboratory
–
Supply of single-use medical devices, consumables and laboratory materials
$1,432
Supply of laboratory reagents together with the lease of analyzers
$26,623

Trademarks

The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2018.

MarkNumberClassesStatusProtected until
BIOMAXIMA Z.4861371, 5, 9, 10, 26, 29, 35, 39, 42, 44Protected May 21, 2028
MarkProtected until
BIOMAXIMA May 21, 2028

Job offers

The company lists 4 job openings on its own careers page: biomaxima.com/kariera.

Position
Production worker – microbiological media production department
Student internship
Sales representative (m/f) (Silesian, Opole and Lesser Poland voivodeships)

Authorized Representatives

Patrycja Anna Paniak-Sankowska age 49 – Attorney-in-fact (joint)
Henryk Marian Lewczuk age 66 – Management Board Member
Piotr Janowski age 61 – Management Board Member
Łukasz Maria Urban age 55 – President of the Management Board

Manner of representation

In the case of a multi-member management board, the joint action of two members of the management board or of one member of the management board jointly with a commercial proxy is required to submit declarations and to sign on behalf of the company.

Supervisory board

Alina Aneta Urban age 52 – Supervisory Board Member
Andrzej Jerzy Mikosz age 61 – Supervisory Board Member
Krzysztof Andrzej Mikosz age 34 – Supervisory Board Member
Dominika Anna Kaliszewska age 56 – Supervisory Board Member
Włodzimierz Paweł Kocon age 66 – Supervisory Board Member

Beneficial owners

Biomaxima is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Bank accounts

Registered as a VAT taxpayer on 2002-09-16.

  • Bank Gospodarstwa Krajowego
    Bank Gospodarstwa Krajowego
    74 1130 1206 0028 9181 2120 0001
  • Bank Pekao SA
    51 1240 5497 1787 0010 6544 0473
  • Bank Millennium
    85 1160 2202 0000 0003 4504 3406

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Jan 26, 2011Merger plan

Public aid

44 public aid cases recorded, with a total value of $4,945,134.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$14,675
De minimis aid (in accordance with Commission Regulation 2023/2831)
$11,217
De minimis aid (in accordance with Commission Regulation 2023/2831)
$9,581

European Funds

20 projects co-financed from European Funds recorded, with total EU co-financing of $5,635,659.

ProjectEU co-financing
Implementation of Biomaxima's R&D results on new gradient MIC strip tests
$259.8K
Promotion of Biomaxima products through participation in international trade fairs
$70,856
Increasing the competitiveness of Biomaxima by implementing the results of R&D work on new paper antibiotic disks
$275.7K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Radiometer sp. z o.o.
Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss Biomed S.A.
Euroimmun Polska sp. z o.o.
PZ Cormay S.A.
Synthaverse S.A.
Hydrex Diagnostics sp. z o.o.
Biomerieux Ssc Europe sp. z o.o.
Bacto - Tech sp. z o.o.
BIO-Ksel sp. z o.o.
Kleverlab sp. z o.o.

Change history

DateEvent
2023-09-01Share capital reduction
2023-04-05Share capital increase
2022-03-31Share capital increase
2021-02-26Share capital increase
2020-04-28Share capital increase

FAQ

Last updated: 2026-06-19